Overview
Paul Radensky assessed the Protecting Access to Medicare Act (PAMA) impact on clinical laboratories, saying that because most hospitals derive their revenues outside of the clinical lab fee schedule or fall short of the fee schedule threshold they would be excluded from PAMA reporting. “The concern is that the data may not be representative,” of what the commercial market is paying for tests, which could drive down PAMA reimbursement rates, he added.
